Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Is The Present And Forecasted Size Of The Minimal Residual Disease Testing Market?
The market size of minimal residual disease testing has seen substantial growth in recent years. An expansion from $1.59 billion in 2024 to $1.8 billion in 2025 with a compound annual growth rate (CAGR) of 12.9% is expected. The growth witnessed in the historical phase is attributed to advancements in cancer research, the need for treatment monitoring, clinical evidence, regulatory assistance, and enhancements in patient outcomes.
The market size for minimal residual disease testing is projected to experience a swift expansion in the imminent years, hitting the mark of “$2.91 billion by 2029”, at a compound annual growth rate (CAGR) of 12.8%. This surge during the forecast period is credited to rising cancer cases, breakthroughs in therapy, precision medicine inclinations, a move towards early diagnosis, and integration within the healthcare system. Key trends during this period involve the inclusion of liquid biopsy procedures, emphasis on early relapse detection, the growth of MRD testing in clinical studies, increasing use in pediatric oncology, and partnerships for research and development.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
Which Key Factors Are Fueling Growth In The Minimal Residual Disease Testing Market?
The escalating occurrence of cancer is likely to spur the expansion of the minimal residual disease testing market in the near future. Cancer is defined as a situation when certain cells from the body grow uncontrollably and invade other parts of the body. The main method of detecting the stages of cancer is through minimal residual disease testing, as it is a highly sensitive technique to identify cancer cells in the human body. This aids in the early prevention of the disease in cancer patients, consequently stimulating the minimal residual disease testing market. For example, in 2022, the American Cancer Society Inc., a US-based nonprofit organization, disclosed in their reports that around 1.9 million new cases of cancer are expected to be diagnosed, resulting in an estimated 609,360 cancer-related deaths in the United States in the same year. Hence, the rising occurrence of cancer is fuelling the expansion of the minimal residual disease testing market.
What Is The Segment Breakdown Of The Minimal Residual Disease Testing Market?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
How Are Global Trends Impacting The Development Of The Minimal Residual Disease Testing Market?
The emergence of product innovations is a leading trend that’s becoming increasingly influential within the minimal residual disease testing market. Dominant companies in the market are introducing novel products in an effort to maintain their market foothold. For example, Twist Bioscience, a US-based firm specializing in synthetic biology and genomics, unveiled their new product, the Twist MRD Panel, in 2022. This initiative aims to propel pioneering efforts in the research and development of minimal residual disease detection in cancer screening procedures. The Twist MRD Panel, an adaptable gene panel, can identify minutely low levels of residual cancer cells in patient’s blood. Its design promotes supreme flexibility and customization, capable of seamless integration into a standard next-generation sequencing (NGS) procedure and is capable of detecting minimum residual disease (MRD) in a mere five days.
Which Companies Are Contributing Significantly To The Minimal Residual Disease Testing Market Growth?
Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Access The Complete Report Here:
Which Region Is Leading Innovation In The Minimal Residual Disease Testing Market?
North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
